Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: JOEBT1 who wrote (14082)	2/2/1998 6:07:00 PM
From: bob smith	Read Replies (2) \| Respond to of 32384

Oh yea, same old story. You've been saying these same things for years now, and look where we are, right where we started! I'm not so sure you believe in what you're saying any more then I do... Today's test told me a lot.

To: JOEBT1 who wrote (14082)	2/3/1998 4:24:00 PM
From: Andrew H	Read Replies (2) \| Respond to of 32384

>>When the market realizes the potential for blockbuster drugs LGND will explode to the up side. For example Targetrin / panretin is as good as tamoxifen for breast cancer and the combination (tamoxifen and Targretrin or Panretin) is syngergistic and and should be more effective than either alone. FWIW I'm looking to do more buying.<< Targretin is as good as tamoxifen in RATS at preventing breast cancer tumors when the rats are injected with breast cancer. That's a far cry from what you suggest in the above statement.